Exploring IB6 as a Therapeutic Target in Non–Small Cell Lung Cancer

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for investigating IB6 as a therapeutic target in lung cancer.

EP. 1: Treatment Approaches and Unmet Needs in Second-Line Advanced NSCLC

September 22nd 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in second-line non–small cell lung cancer.

EP. 2: Rationale for Evaluating IB6 as a Potential Therapeutic Target in NSCLC

September 22nd 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the rationale for evaluating IB6 as a target in non–small cell lung cancer.

EP. 3: Evaluation of Sigvotatug Vedotin Monotherapy in Previously Treated, Nonsquamous NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin in nonsquamous NSCLC.

EP. 4: Exploring Sigvotatug Vedotin–Based Combinations in Advanced NSCLC

October 7th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss the investigation of sigvotatug vedotin plus pembrolizumab in NSCLC.

EP. 5: Novel Biomarkers to Watch in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.

EP. 6: Unmet Needs to Address in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.